Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...

Tarlatamab improved PFS and OS over chemotherapy as second-line treatment in patients with SCLC in the phase 3 DeLLphi-304 trial.

One patient had immune effector cell-associated neurotoxicity syndrome (ICANS; grade 1), which resolved. No clinical tumor lysis syndrome was observed.

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association ...

progressive multifocal leukoencephalopathy (a viral infection affecting the brain and nervous system) tumor lysis syndrome (a buildup of chemicals in the bloodstream) infusion-related reaction ...

It’s bedtime, but your legs feel like they need to move as soon as you lie down. Sound familiar? You may have restless legs syndrome.

The tumor suppressor p53 is a transcription factor that controls the expression of hundreds of genes. Emerging evidence suggests that the p53-induced RNA-binding protein ZMAT3 is a key splicing ...

The girl's symptoms have worsened since the family of mixed-immigration status was deported to Mexico in February, her mother told NBC News exclusively. “We’re fighting for my girl’s life." ...

Tumor lysis syndrome: Caused by the fast breakdown of cancer cells. Signs include nausea, vomiting, diarrhea, and lack of energy ...

Due to the small size and height of the Eva1 molecule, Eva1CAR-T cells can form more effective immune synapses—contact zones between an immune cell and its target tumor cells. The formation of ...